Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

HM Lokhorst, I Schmidt-Wolf, Pieter Sonneveld, Ronnie van der Holt, H Martin, R Barge, U Bertsch, J Schlenzka, G (Gerard) Bos, S Croockewit, S Zweegman, I Breitkreuz, Pauline Joosten, C Scheid, M van Marwijk-Kooy, HJ Salwender, MHJ van Oers, R Schaafsma, R Naumann, H SinnigeI Blau, G Verhoef, O de Weerdt, P Wijermans, S Wittebol, U Duersen, E Vellenga, H Goldschmidt

Research output: Contribution to journalArticleAcademicpeer-review

133 Citations (Scopus)


In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.
Original languageUndefined/Unknown
Pages (from-to)124-127
Number of pages4
Issue number1
Publication statusPublished - 2008

Research programs

  • EMC MM-02-41-03

Cite this